Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors

Current Topics in Medicinal Chemistry

Volumn 7, Issue 4, 2007, Pages 375-387

  Haviv, H ^a   Wong, D M ^b   Silman, I ^a   Sussman, Joel L ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Bivalent ligand; Chelate effect; E2020; Huperzine A; Hupyridone; Tacrine

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMBENONIUM; AMYLOID BETA PROTEIN; BIS 7 TACRINE; BW 284C 51; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DONEPEZIL; ESTERASE INHIBITOR; HUPERZINE A; HUPERZINE B; HUPYRIDONE; MONOAMINE OXIDASE INHIBITOR; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; IC 50; MOLECULAR MODEL; NEUROPROTECTION; PROTEIN AGGREGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE INHIBITORS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SESQUITERPENES; TORPEDO;

EID: 33847671821     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941215     Document Type: Review

References (76)

1. Ma, X.; Gang, D. R. The Lycopodium alkaloids. Nat. Prod. Rep. 2004, 21, 752-772.
2. Kawakami, Y.; Inoue, A.; Kawai, T.; Wakita, M.; Sugimoto, H.; Hopfinger, A. J. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. Lett. 1996, 4, 1429-1446.
3. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297-307.
4. Nightingale, S. L. Donepezil approved for treatment of Alzheimer's disease. JAMA 1997, 277, 10.
5. Greenblatt, H. M.; Kryger, G.; Lewis, T.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3Å resolution. FEBS Lett. 1999, 463, 321-326.
6. Bar-On, P.; Millard, C. B.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J. L.; Silman, I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002, 41, 3555-3564.
7. Bai, D. L.; Tang, X. C.; He, X. C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000, 7, 355-374.
8. Wang, R.; Yan, H.; Tang, X. C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006, 27, 1-26.
9. http://www.clinicaltrials.gov/showNCT00083590
10. Gordon, R. K.; Haigh, J. R.; Garcia, G. E.; Feaster, S. R.; Riel, M. A.; Lenz, D. E.; Aisen, P. S.; Doctor, B. P. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem. Biol. Interact. 2005, 157-158, 239-246.
11. DeKosky, S. T.; Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27, 457-464.
12. Bartus, R. T.; Dean, R. L. r.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-414.
13. Davis, K. L.; Powchik, P. Tacrine. Lancet 1995, 345, 625-630.
14. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271, 992-998.
15. Bergmann, F.; Wilson, I. B.; Nachmansohn, D. The inhibitory effect of stilbamidine, curare and related compounds and its relationship to the active groups of acetylcholine esterase. Action of stilbamidine upon nerve impulse conduction. Biochim. Biophys. Acta 1950, 6, 217-224.
16. Austin, L.; Berry, W. K. Two selective inhibitors of cholinesterase. Biochem. J. 1953, 54, 695-700.
17. Lands, A. M.; Hoppe, J. O.; Arnold, A.; Kirchner, F. K. An investigation of the structure-activity correlations within a series of ambenonium analogs. J. Pharmacol. Exp. Ther. 1958, 123, 121-127.
18. Du, D. M.; Carlier, P. R. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr. Pharm. Des. 2004, 10, 3141-3156.
19. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050.
20. Long, Y. Q.; Jiang, X. H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 2004, 47, 2561-2573.
21. Lee, G. F.; Lazarus, R. A.; Kelley, R. F. Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins. Biochemistry 1997, 36, 5607-5611.
22. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253, 872-879.
23. Dougherty, D. A. Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996, 271, 163-168.
24. Sussman, J. L.; Silman, I. Acetylcholinesterase: structure and use as a model for specific cation-protein interactions. Curr. Opin. Struct. Biol. 1992, 2, 721-729.
25. Changeux, J.-P. Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs. Mol. Pharmacol. 1996, 2, 369-392.
26. Silman, I.; Sussman, J. L. Structural studies on acetylcholinesterase. In Cholinesterases and Cholinesterase Inhibitors, Giacobini, E. Ed. Martin Dunitz: London, 2000; pp 9-25.
27. Greenblatt, H. M.; Dvir, H.; Silman, I.; Sussman, J. L. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J. Mol. Neurosci. 2003, 20, 369-383.
28. Sussman, J. L.; Harel, M.; Silman, I. Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem. Biol. Interact. 1993, 87, 187-197.
29. Felder, C. E.; Harel, M.; Silman, I.; Sussman, J. L. Structure of a complex of the potent and specific inhibitor BW284C51 with Torpedo californica acetylcholinesterase. Acta Crystallogr. D Biol. Crystallogr, 2002, 58, 1765-1771.
30. Taylor, P.; Radic, Z. The cholinesterases: from genes to proteins. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 281-320.
31. DeLano, W. L. The PyMOL Molecular Graphics System, 0.99; DeLano Scientific: San Carlos, CA, USA, 2002.
32. Raves, M. L.; Harel, M.; Pang, Y. P.; Silman, I.; Kozikowski, A. P.; Sussman, J. L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 1997, 4, 57-63.
33. Pang, Y. P.; Kozikowski, A. P. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies. J. Comput. Aided. Mol. Des. 1994, 8, 669-681.
34. Rydberg, E. H.; Brumshtein, B.; Greenblatt, H. M.; Wong, D. M.; Shaya, D.; Carlier, P. R.; Pang, Y.-P.; Silman, I.; Sussman, J. L. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge. J. Med. Chem. 2006, 49, 5491-5500.
35. Fu, H.; Li, W.; Lao, Y.; Luo, J.; Lee, N. T.; Kan, K. K.; Tsang, H. W.; Tsim, K. W.; Pang, Y.; Li, Z.; Chang, D. C.; Li, M.; Han, Y. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J. Neurochem. 2006, 98, 1400-1410.
36. Li, W.; Lee, N. T.; Fu, H.; Kan, K. K.; Pang, Y.; Li, M.; Tsim, K. W.; Li, X.; Han, Y. Neuroprotection via inhibition of nitric oxide synthase by bis(7)-tacrine. Neuroreport 2006, 17, 471-474.
37. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
38. Alvarez, A.; Alarcon, R.; Opazo, C.; Campos, E. O.; Munoz, F. J.; Calderon, F. H.; Dajas, F.; Gentry, M. K.; Doctor, B. P.; De Mello, F. G.; Inestrosa, N. C. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. 1998, 18, 3213-3223.
39. Alvarez, A.; Opazo, C.; Alarcon, R.; Garrido, J.; Inestrosa, N. C. Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 1997, 272, 348-361.
40. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16, 881-891.
41. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide formation. Biochemistry 2001, 40, 10447-10457.
42. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416.
43. Silman, I.; Sussman, J. L. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr. Opin. Pharmacol. 2005, 5, 293-302.
44. Paraoanu, L. E.; Layer, P. G. Mouse acetylcholinesterase interacts in yeast with the extracellular matrix component laminin-1β. FEBS Lett. 2004, 576, 161-164.
45. Jin, G.; Luo, X.; He, X.; Jiang, H.; Zhang, H.; Bai, D. Synthesis and docking studies of alkylene-linked dimers of (-)-huperzine A. Arzneimittelforschung 2003, 53, 753-757.
46. Dvir, H.; Jiang, H. L.; Wong, D. M.; Harel, M.; Chetrit, M.; He, X. C.; Jin, G. Y.; Yu, G. L.; Tang, X. C.; Silman, I.; Bai, D. L.; Sussman, J. L. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: Structural evidence for an active site rearrangement. Biochemistry 2002, 41, 10810-10818.
47. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646-23649.
48. Feng, S.; Wang, Z.; He, X.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X.; Bai, D. Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J. Med. Chem. 2005, 48, 655-657.
49. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.
50. Han, Y. F.; Li, C. P.; Chow, E.; Wang, H.; Pang, Y. P.; Carlier, P. R. Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Bioorg. Med. Chem. Lett. 1999, 7, 2569-2575.
51. Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product Angew. Chem. Int. Ed. Engl. 2000, 39, 1775-1777.
52. Wong, D. M.; Greenblatt, H. M.; Dvir, H.; Carlier, P. R.; Han, Y. F.; Pang, Y. P.; Silman, I.; Sussman, J. L. Acetylcholinesterase complexed with bivalent ligands related to huperzine A: experimental evidence for species-dependent protein-ligand complementarity. J. Am. Chem. Soc. 2003, 125, 363-373.
53. Xu, Y.; Shen, J.; Luo, X.; Siltman, I.; Sussman, J. L.; Chen, K.; Jiang, H. How does huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J. Am. Chem. Soc. 2003, 125, 11340-11349.
54. Bourne, Y.; Taylor, P.; Bougis, P. E.; Marchot, P. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J. Biol. Chem. 1999, 274, 2963-2970.
55. Dvir, H.; Wong, D. M.; Harel, M.; Barril, X.; Orozco, M.; Luque, F. J.; Muñoz-Torrero, D.; Camps, P.; Rosenberry, T. L.; Silman, I.; Sussman, J. L. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. Biochemistry 2002, 41, 2970-2981.
56. Zeng, F.; Jiang, H.; Zhai, Y.; Zhang, H.; Chen, K.; Ji, R. Synthesis and acetylcholinesterase inhibitory activity of huperzine A-E2020 combined compound. Bioorg. Med. Chem. Lett. 1999, 9, 3279-3284.
57. Winblad, B.; Kilander, L.; Eriksson, S.; Minthon, L.; Batsman, S.; Wetterholm, A. L.; Jansson-Blixt, C.; Haglund, A. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367, 1057-1065.
58. Gemma, S.; Gabellieri, E.; Huleatt, P.; Fattorusso, C.; Borriello, M.; Catalanotti, B.; Butini, S.; De Angelis, M.; Novellino, E.; Nacci, V.; Belinskaya, T.; Saxena, A.; Campiani, G. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J. Med. Chem. 2006, 49, 3421-3425.
59. Mesulam, M. M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002, 110, 627-639.
60. Greig, N. H.; Utsuki, T.; Ingram, D. K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q. S.; Mamczarz, J.; Holloway, H. W.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D. K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17213-17218.
61. Radic, Z.; Taylor, P. Structure and function of cholinesterases. In Toxicology of organophosphate and carbamate compounds, Gupta, R. C. Ed. Elsevier Academic Press: Amsterdam, 2006; pp 161-186.
62. Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 2003, 46, 1-4.
63. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad Sci. U.S.A. 1993, 90, 9031-9035.
64. Haviv, H.; Wong, D. M.; Greenblatt, H. M.; Carlier, P. R.; Pang, Y. P.; Silman, I.; Sussman, J. L. Crystal packing mediates enantioselective ligand recognition at the peripheral site of acetylcholinesterase. J. Am. Chem. Soc. 2005, 127, 11029-11036.
65. Bourne, Y.; Kolb, H. C.; Radic, Z.; Sharpless, K. B.; Taylor, P.; Marchot, P. Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1449-1454.
66. Colletier, J. P.; Sanson, B.; Nachon, F.; Gabellieri, E.; Fattorusso, C.; Campiani, G.; Weik, M. Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor. J. Am. Chem. Soc. 2006, 128, 4526-4527.
67. Carlier, P. R.; Chow, E. S.; Han, Y.; Liu, J.; El Yazal, J.; Pang, Y. P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. J. Med. Chem. 1999, 42, 4225-4231.
68. Carlier, P. R.; Du, D. M.; Han, Y.; Liu, J.; Pang, Y. P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335-2338.
69. Greenblatt, H. M.; Guillou, C.; Guenard, D.; Argaman, A.; Botti, S.; Badet, B.; Thal, C.; Silman, I.; Sussman, J. L. The complex of a bivalent derivative of galanthamine with Torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J. Am. Chem. Soc. 2004, 126, 15405-15411.
70. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radic, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. Engl. 2002, 41, 1053-1057.
71. Castro, A.; Martinez, A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev. Med. Chem. 2001, 1, 267-272.
72. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4- Benzyl(methyl)amino]methyl]phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med Chem. 2003, 46, 2279-2282.
73. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Finberg, J.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B.; Weinstock, M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 2002, 45, 5260-5279.
74. Farias, G. G.; Godoy, J. A.; Vazquez, M. C.; Adani, R.; Meshulam, H.; Avila J.; Amitai, G.; Inestrosa, N. C. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 2005, 18, 176-183.
75. Amitai, G.; Adani, R.; Fishbein, E.; Meshulam, H.; Laish, I.; Dachir, S. Bifunctional compounds eliciting anti-inflammatory and anti-cholinesterase activity as potential treatment of nerve and blister chemical agents poisoning. J. Appl, Toxicol. 2006, 26, 81-87.
76. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48, 360-363.